triazoles has been researched along with suvorexant in 180 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 116 (64.44) | 24.3611 |
2020's | 64 (35.56) | 2.80 |
Authors | Studies |
---|---|
Boss, C; Brisbare-Roch, C; Gatfield, J; Jenck, F | 1 |
Anderson, WB; Bednar, RA; Bogusky, MJ; Breslin, MJ; Bruno, JG; Cabalu, TD; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Garson, SL; Harrell, CM; Hartman, GD; Koblan, KS; Lemaire, W; McGaughey, GB; Mercer, SP; Murphy, KL; Prueksaritanont, T; Reiss, DR; Renger, JJ; Roecker, AJ; Roller, S; Schreier, JD; Tang, C; Whitman, DB; Winrow, CJ; Young, SD | 1 |
Breslin, MJ; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Reiss, DR; Renger, JJ; Stevens, J; Tannenbaum, PL; Winrow, CJ | 1 |
Baxter, CA; Brands, KM; Cleator, E; Krska, SW; Reamer, RA; Strotman, NA; Wallace, DJ; Wright, TJ | 1 |
Fleitz, FJ; Mangion, IK; Sherry, BD; Yin, J | 1 |
Willyard, C | 1 |
Hopkins, CR | 1 |
Budd, K; Herring, WJ; Hutzelmann, J; Lines, C; Liu, K; Michelson, D; Roth, T; Snavely, D; Snyder, E | 1 |
Mieda, M; Sakurai, T | 1 |
Calder, N; Chodakewitz, J; Ermlich, S; Kennedy, WP; Lewis, N; Li, X; Lines, C; Ma, J; Mangin, E; Murphy, GM; Rosen, L; Sun, H; Wilbraham, D; Yee, KL | 1 |
Crow, JM | 1 |
Czajkowska, B; Krzystanek, M; Lapray, D; Markowski, G; Pałasz, A; Peyron, C; Rojczyk-Gołębiewska, E; Skowronek, R; Wiaderkiewicz, R | 1 |
Johnson, MS | 1 |
Osborne, R | 1 |
Badiger, S; Behnke, D; Betschart, C; Chaudhari, V; Cotesta, S; Fendt, M; Gee, CE; Hintermann, S; Hoyer, D; Jacobson, LH; Laue, G; Ofner, S; Pandit, C; Wagner, J | 1 |
Binns, J; Brunner, J; Coleman, PJ; Cui, D; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Kuduk, SD; McDonald, T; Renger, JJ; Savitz, A; Stevens, J; Stiteler, M; Tannenbaum, PL; Tye, SJ; Uslaner, J; Winrow, CJ; Yao, L; Yee, KL | 1 |
Hoyer, D; Jacobson, LH | 1 |
Mediavilla, C; Risco, S | 1 |
Ball, R; Bayly, CI; Bogusky, M; Breslin, MJ; Coleman, PJ; Cox, CD; McGaughey, G; Pitzenberger, S; Schreier, JD | 1 |
Benca, RM; Chengan-Liu, M; Cohn, M; Herring, WJ; Hutzelmann, J; Krystal, AD; Lines, C; Michelson, D; Paradis, E; Roth, T; Snavely, DB; Snyder, E; Walsh, JK | 1 |
Riemann, D; Spiegelhalder, K | 1 |
Traynor, K | 1 |
Herring, WJ; Lines, C; Ma, J; Roth, T; Snyder, E; Svetnik, V | 1 |
Yang, LP | 1 |
Citrome, L | 1 |
Howland, RH | 1 |
Sheridan, C | 1 |
Callander, GE; Hoyer, D; Jacobson, LH | 1 |
El-Mallakh, RS; Kommisetti, S; Lippmann, S; Puvvada, SC; Reddy, A | 1 |
Preskorn, SH | 2 |
Benca, RM; Budd, K; Connor, KM; Froman, S; Herring, WJ; Hutzelmann, J; Ivgy-May, N; Krystal, AD; Leibensperger, H; Lines, C; Liu, K; Michelson, D; Rosenberg, R; Roth, T; Sangal, RB; Snavely, DB; Snyder, E; Walsh, JK | 1 |
Kolb, P; Mobarec, JC; Rosenbaum, DM; Yin, J | 1 |
Hermans, A; Kesisoglou, F; Miller, J; Neu, C; Palcza, J; Yee, KL | 1 |
Kryger, M; Lines, C; Palcza, J; Rosenberg, R; Rowe, J; Siringhaus, T; Sun, H; Troyer, MD; Wagner, JA | 1 |
Aspesi, AV; Evoy, KE; Patel, KV | 1 |
Donikyan, M; Lines, C; Liu, R; Louridas, B; Marsilio, S; McCrea, J; Sun, H; Troyer, MD; Uemura, N; Wagner, J; Zammit, G | 1 |
Bautmans, A; Heirman, I; Jongen, S; Laethem, T; Li, X; McCrea, J; Palcza, J; Sun, H; Troyer, MD; Van Leeuwen, CJ; Van Oers, AC; Vermeeren, A; Vuurman, EF; Wrishko, R | 1 |
Card, D; Gipson, A; Kryger, M; Lines, C; Palcza, J; Rosenberg, R; Sun, H; Troyer, MD; Wagner, JA | 1 |
Iwata, N; Kishi, T; Matsunaga, S | 1 |
Breidinger, SA; Mangin, E; Simpson, RC; Woolf, EJ | 1 |
Gill, S; Li, X; Liu, W; Mangin, E; McCrea, J; Morrison, D; Panebianco, D; Sun, H; Troyer, MD; Wagner, JA; Yee, KL | 1 |
Sutton, EL | 1 |
Cabalu, T; Cui, D; Li, X; Liu, B; Liu, W; Maciolek, C; McCrea, JB; Prueksaritanont, T; Small, J; Smith, S; Yee, KL | 1 |
Owen, RT | 1 |
Hussar, DA | 1 |
Babaoglu, K; Brautigam, CA; Clark, L; Coleman, PJ; Gotter, AL; Harrell, CM; Renger, JJ; Roecker, AJ; Rosenbaum, DM; Scheuermann, TH; Shao, Z; Winrow, CJ; Yin, J | 1 |
Lee, GR; Seok, C | 1 |
Hori, S; Miki, A; Sawada, Y; Shihyakugari, A | 1 |
Connor, KM; Herring, WJ; Lines, C; Ma, J; Michelson, D; Snyder, E; Svetnik, V | 1 |
Bondiskey, P; Cha, JH; Faulknor, J; Kennedy, WP; Levy-Cooperman, N; Lewis, NM; Li, X; Liu, W; McCrea, JB; Panebianco, DL; Schoedel, KA; Sellers, EM; Sun, H; Troyer, MD; Wagner, JA | 1 |
Gauld, AR | 1 |
Stahl, SM | 1 |
Benca, RM; Connor, KM; Herring, WJ; Hutzelmann, J; Krystal, AD; Lines, C; Matzura-Wolfe, D; Michelson, D; Roth, T; Snavely, DB; Snyder, E; Walsh, JK; Zhang, Y | 3 |
Bautmans, A; Heirman, I; Jongen, S; Laethem, T; Li, X; McCrea, J; Palcza, J; Sun, H; Troyer, MD; Van Oers, AC; Vermeeren, A; Vets, E; Vuurman, EF; Wrishko, R | 1 |
Aoki, I; Hisada, S; Ishine, T; Renger, JJ; Tanaka, Y; Winrow, CJ | 1 |
Drexel, M; Gargano, C; Ma, J; Mayleben, D; Stoch, SA; Struyk, A; Svetnik, V | 1 |
Ishii, Y; Ito, H; Kon, K; Sakurai, T; Sasahara, M; Sasaoka, T; Takahara, S; Toyooka, N; Tsuneki, H; Wada, T; Yamazaki, M; Yanagisawa, M | 1 |
Carson, M; Kerrigan, S | 1 |
Coleman, PJ; Gotter, AL; Herring, WJ; Renger, JJ; Winrow, CJ | 1 |
Bryand, K; Kerrigan, S; Sullinger, S | 1 |
Kitaguchi, H; Kuriyama, A; Shindo, K; Tabata, H; Yamao, F | 1 |
Edmonds, C; Swanoski, M | 1 |
Born, S; Briscoe, R; Gauvin, DV; Mukherjee, S | 1 |
Kuriyama, A; Tabata, H | 1 |
Al-Rashood, KA; Al-Rashood, ST; Ezzeldin, E; Iqbal, M; Khalil, NY | 1 |
Barker, DJ; España, RA; Gentile, TA; Muschamp, JW; Shaw, JK; Simmons, SJ | 1 |
Inoue, T; Kasai, K; Kondo, S; Morita, M; Wada, A | 1 |
Horiuchi, F; Kawabe, K; Nishimoto, K; Ochi, M; Oka, Y; Ueno, SI | 1 |
Brailoiu, E; Connelly, KL; Gentile, TA; Muschamp, JW; Simmons, SJ; Watson, MN; Zhang, Y | 1 |
Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H | 3 |
Gentile, TA; Martorana, R; Muschamp, JW; Philogene-Khalid, H; Rawls, SM; Simmons, SJ; Su, S; Tran, FH; Xu, X | 1 |
Nagamine, T; Nakamura, M | 1 |
Koch, GG; Snyder, E; Sun, H | 1 |
Hope, J; Keks, NA; Keogh, S | 1 |
Furmaga, K; Petrous, J | 1 |
Herring, WJ; Lines, C; Roth, T; Scammell, TE; Snyder, ES; Svetnik, V; Tao, P | 1 |
Hamuro, A; Honda, M; Wakaura, Y | 1 |
Sasaoka, T; Tsuneki, H; Wada, T | 1 |
Hara, K; Ikematsu, N; Kashiwagi, M; Kubo, SI; Matsusue, A; Takayama, M; Waters, B | 1 |
Iizuka, Y; Lefor, AK; Masuyama, T; Nagatomo, K; Ogi, K; Sanui, M; Sasabuchi, Y; Yagihashi, S; Yoshida, N | 1 |
Arai, S; Goto, A; Hata, C; Honda, Y; Ichikawa, Y; Kessoku, T; Komori, T; Kusakabe, A; Matsuura, T; Miyashita, Y; Nakajima, A; Saito, Y; Sukegawa, A; Yashiro, R; Yoshida, H; Yoshimi, A | 1 |
Nakao, M; Nishimura, S | 1 |
Hayakawa, T; Moriyama, S; Takeuchi, Y; Yanai, H | 1 |
Cabalu, T; Lewis, N; Liu, W; McCrea, J; Panebianco, D; Ramael, S; Wrishko, RE; Yee, KL | 1 |
Kerrigan, S; Skillman, B | 4 |
Campbell, EJ; Lawrence, AJ; Marchant, NJ | 1 |
Maruyama, T; Sakurai, S; Tamura, K | 1 |
Fu, J; Sun, S | 1 |
Al-Rashood, KA; Ezzeldin, E; Iqbal, M; Khalil, NY | 1 |
Kawada, K; Miyamura, M; Ohta, T; Tanaka, K; Tanaka, S | 1 |
Herring, WJ; Krystal, AD; Michelson, D; Roth, T | 1 |
Nakamura, K; Yasui-Furukori, N; Yoshida, K | 1 |
Connor, KM; Herring, WJ; Lines, C; Michelson, D; Morin, CM; Snavely, DB; Snyder, E | 1 |
Asai, Y; Hara, M; Iwakura, M; Maeda, Y; Miyazaki, M; Sano, H | 2 |
Benedict, J; Ehlers, CL; Sanchez-Alavez, M; Wills, DN | 1 |
Akihiro, S; Daida, H; Fujibayashi, K; Kasai, T; Matsumoto, H; Nishizaki, Y; Nojiri, S; Ogita, M; Ono, N; Shitara, J; Suda, S; Suwa, S; Yanagisawa, N; Yatsu, S | 1 |
Bunker, A; Karhu, L; Magarkar, A; Xhaard, H | 1 |
Gentile, TA; Simmons, SJ | 1 |
Chakravarthy, M; Kraft, WK; Liu, W; Mangin, E; Martinez-Cantarin, MP; McCrea, JB; Panebianco, D; Wrishko, RE; Yee, KL | 1 |
Doumas, M; Imprialos, KP; Karagiannis, A; Papademetriou, V; Stavropoulos, K | 1 |
Kanegae, H; Kario, K; Okawara, Y; Tomitani, N; Tsukamoto, M; Yagi, K; Yamasaki, K; Yamazaki, S | 1 |
Kinoshita, T; Koshikawa, K; Matsumura, T; Nagashima, K; Sakao, S; Tatsumi, K; Terada, J; Yahaba, M; Yoshimura, C | 1 |
Yanagisawa, M | 1 |
Cabanas, M; Cho, YH; Garret, M; Jeantet, Y; Pistono, C; Puygrenier, L; Rakesh, D | 1 |
Connor, DF; Prieto, DI; Zehgeer, AA | 1 |
Bolli, MH; Boss, C; Brotschi, C; Gatfield, J; Heidmann, B; Jenck, F; Roch, C; Sifferlen, T; Treiber, A; Williams, JT | 1 |
Iwata, N; Kishi, T; Kubo, M; Matsui, Y; Matsunaga, S; Ninomiya, K; Nomura, I; Okuya, M; Okuyama, Y; Oya, K; Sakuma, K | 1 |
Atkinson, R; Cheng, P; Cuamatzi-Castelan, A; Drake, CL; Fellman-Couture, C; Kalmbach, DA; Roth, T; Singh, M; Tonnu, CV; Tran, KM | 1 |
Sercel, ZP; Stoltz, BM; Sun, AW | 1 |
Cardoso, R; Farah, B; Goodarzi, Z; Harricharan, S; Leech, J; Morin, CM; Morra, D; Nincic, V; Rios, P; Straus, SE; Tricco, AC | 1 |
Asai, Y; Iwakura, M; Maeda, Y; Miyazaki, M; Sano, H; Takeuchi, Y | 1 |
Bonomo, Y; Campbell, EJ; Lawrence, AJ; Norman, A | 1 |
Akizuki, N; Eguchi, H; Hashimoto, N; Hatta, K; Horikawa, N; Ito, S; Kishi, Y; Kurata, A; Muto, H; Nakamura, H; Nakanishi, Y; Nishio, Y; Ohmori, T; Suda, K; Taira, T; Takeuchi, T; Tsuchida, K; Uchimura, N; Usui, C; Wada, K | 1 |
Iba, Y; Kimura, T; Murai, H; Suzuki, H; Tanji, H | 1 |
Herring, WJ; Lines, C; Roth, T; Snyder, ES; Svetnik, V; Tao, P | 1 |
Bliwise, D; Budd, K; Ceesay, P; Herring, WJ; Hutzelmann, J; Lines, C; Michelson, D; Snyder, E; Stevens, J | 1 |
Aston-Jones, G; Aurora, RN; Cooperman, NA; Fragale, JE; James, MH; Langleben, DD | 1 |
Bazan, L; Koshorek, G; Roehrs, T; Roth, T; Verkler, J; Withrow, D | 1 |
Babu, JM; Balakumaran, K; Basavaiah, K; Devi, DR; Kumar Reddy, DN; Rajana, N | 1 |
Cai, HY; He, YX; Li, YY; Qi, JS; Wang, C; Wang, ZJ; Wu, MN; Yan, XD; Zhang, J; Zhou, F | 1 |
Dujardin, S; Pevernagie, D; Pijpers, A | 1 |
Araki, M; Iwata, H; Koiwa, J; Masuda, K; Okamura, M; Okuno, Y; Tanaka, T; Yamanaka, M | 1 |
Ando, M; Fujimoto, K; Hashida, T; Ikesue, H; Kobaru, T; Kume, N; Okusada, S; Shimizu, R; Tanaka, M; Tomita, H; Torii, H | 1 |
Adams, AD; Brown, JN; Pepin, MJ | 1 |
Hernandez, B; Holty, JE; Joyce, DS; McBean, A; Quevedo, YL; Zeitzer, JM | 1 |
Brian, ML; Clark, JW; Drummond, SPA; Hoyer, D; Jacobson, LH | 1 |
Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Nomura, I; Okuya, M; Sakuma, K | 1 |
Althoff, FC; Azimaraghi, O; Eikermann, M; Fuller, PM; Grabitz, SD; Hammer, M; Patrocinio, M; Platzbecker, K; Rumyantsev, S; Santer, P; Schaefer, MS; Subramaniam, B; Wongtangman, K; Xu, X | 1 |
Fujii, S; Hashimoto, A; Ibe, Y; Ishigo, T; Katano, S; Kimyo, T; Kitagawa, M; Kondo, F; Miyamoto, A; Nakano, K; Nakata, H; Takada, R; Tateishi, R | 1 |
Cui, Y; Shen, J; Wang, P; Xu, S | 1 |
Earl, DC; Van Tyle, KM | 1 |
Ando, Y; Hirose, T; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H; Yoshikawa, F | 1 |
Ashidate, K; Chiba, S; Ichijo, T; Ishibashi, Y; Ishiwata, N; Kato, T; Nishitani, R; Sasabe, M; Shimura, A; Takeuchi, A; Touko, M | 1 |
Iwata, M; Kaneko, K | 1 |
Araki, T; Hashioka, S; Hayashida, M; Inagaki, M; Ito, T; Izuhara, HK; Izuhara, M; Kimura, T; Miura, S; Nagahama, M; Otsuki, K; Saito, Y; Sato, K; Tsuchie, K; Tsumoto, S; Wake, R | 2 |
Kobayashi, T; Okada, T; Suda, S; Takano, M | 1 |
McCleery, J; Sharpley, AL | 1 |
Krishnamurthy, S; Prajapati, SK | 1 |
Murata, T | 1 |
Armacost, KA; Breslin, MJ; Brooun, A; Byrne, NJ; Hall, DL; Hollenstein, K; Hollingsworth, SA; Hong, C; Kern, JC; McDonald, TP; Minnick, C; O'Brien, JA; Partridge, AT; Rada, VL; Rudd, MT; Shipman, JM; Soisson, SM; Stachel, SJ; Strickland, C; Tummala, S; Xiao, L; Zamlynny, B | 1 |
Hashioka, S; Inagaki, M; Izuhara, M; Kawano, K; Otsuki, K | 1 |
Esmaili-Shahzade-Ali-Akbari, P; Hosseinzadeh, H; Mehri, S | 1 |
Arai, T; Ichida, M; Inada, T; Kojima, S; Naito, K; Ozaki, N; Tachibana, M | 1 |
Amano, Y; Horiguchi, S; Iba, Y; Kimura, T; Murai, H; Sugano, A; Yoshimoto, Y | 1 |
Matsumoto, T | 1 |
Garcia, L; Richards-Waugh, L; Tiscione, NB; Yeatman, DT | 1 |
Brooks, JO; Kruse, JL | 1 |
Atkins, N; Citrome, L; Frech, F; Juday, T | 1 |
Akiyama, M; Ishida, H; Kitahara, T; Kouda, K; Matsunaga, K; Saisyo, A; Takasago, M; Takasaki, A; Wakabayashi, K | 1 |
Horikoshi, S; Hoshino, H; Kanno, K; Miura, I; Ochiai, H; Osakabe, Y; Shiga, T; Yabe, H | 1 |
Bliwise, D; Budd, K; Ceesay, P; Ceren, O; Herring, WJ; Hutzelmann, J; Lines, C; Michelson, D; Snyder, E; Stevens, J; Svetnik, V; Wang, TC | 1 |
Benca, R; Botteman, M; Kale, HP; Khandker, R; Meng, W; Qureshi, ZP; Shah, R | 1 |
Dingemanse, J; Kelsh, D; Schoedel, KA; Ufer, M | 1 |
Han, Y; Qin, Z; Tian, Y | 1 |
Bertisch, SM; Cohn, AY; Crawford, S; Erickson, A; Grant, LK; Harder, JA; Joffe, H; McCormick, K; Nathan, MD; Rahman, SA; Srivastava, A; Wiley, A; Winkelman, JW | 1 |
Allocca, G; Chu, J; Cornthwaite-Duncan, L; Daykin, H; Hoyer, D; Jacobson, LH; Keenan, RJ | 1 |
Ito, H; Matsuo, M; Sasaoka, T; Toyooka, N; Tsuneki, H; Yamazaki, M | 1 |
Kaur, H; Krishnamurthy, VB; Singh, J; Yadav, S | 1 |
Berger, AA; Gilbert, E; Hasoon, J; Kaye, AD; Keefe, J; Sottosanti, ER; Thase, ME; Urits, I; Viswanath, O; Winnick, A | 1 |
Birku, K; Kobayashi, I; Lavela, P; Mellman, TA; Sandhu, I | 1 |
Inamoto, A; Iwanami, A; Kondo, S; Okino, K; Suzuki, H; Tokumasu, T; Tomioka, H; Yamada, H | 1 |
Bergeria, CL; Dunn, KE; Finan, PH; Gamaldo, CE; Hammond, AS; Huhn, AS; Strain, EC; Umbricht, A | 1 |
Han, G; Imanishi, A; Kanbayashi, T; Nishino, S; Park, I; Satake, M; Shioya, T; Terui, Y; Uemura, SI | 1 |
Chavan, P; Chikahisa, S; Dalanon, J; Matsuka, Y; Okura, K; Séi, H; Shimizu, N; Shiuchi, T | 1 |
Fukushi, I; Hasebe, Y; Kono, Y; Okada, Y; Onimaru, H; Pokorski, M; Takeda, K; Terada, J; Umeda, A; Yokota, S; Yoshizawa, M | 1 |
Hatton, KW; Hays, LR; Lile, JA; Rayapati, AO; Rush, CR; Stoops, WW; Strickland, JC | 1 |
Ashrafizaadeh, M; Bamdad, F; Farrokhpour, H | 1 |
Kawada, T | 1 |
Bateman, RJ; Lucey, BP | 1 |
38 review(s) available for triazoles and suvorexant
Article | Year |
---|---|
Orexin receptor antagonists: a new concept in CNS disorders?
Topics: Acetamides; Azepines; Central Nervous System Diseases; Humans; Intracellular Signaling Peptides and Proteins; Isoquinolines; Neuropeptides; Orexin Receptors; Orexins; Patents as Topic; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Signal Transduction; Triazoles | 2010 |
ACS chemical neuroscience molecule spotlight on Suvorexant.
Topics: Animals; Azepines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Intracellular Signaling Peptides and Proteins; Neuropeptides; Orexins; Sleep Initiation and Maintenance Disorders; Triazoles | 2012 |
Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Topics: Animals; Azepines; Clinical Trials, Phase III as Topic; Humans; Orexin Receptors; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Sleep Wake Disorders; Triazoles; Wakefulness | 2013 |
Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
Topics: Acetamides; Animals; Azepines; Benzofurans; Humans; Isoquinolines; Models, Biological; Orexin Receptor Antagonists; Orexin Receptors; Piperidines; Pyrimidines; Sleep; Sleep Initiation and Maintenance Disorders; Thiazoles; Triazoles; Wakefulness | 2014 |
Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Topics: Acetamides; Animals; Azepines; Behavior, Addictive; Benzofurans; Feeding Behavior; Humans; Intracellular Signaling Peptides and Proteins; Isoquinolines; Mice; Neuropeptides; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Piperidines; Pyrimidines; Rats; Reward; Sleep; Sleep Initiation and Maintenance Disorders; Thiazoles; Triazoles | 2013 |
[Orexin: clinical and therapeutic implications].
Topics: Animals; Arousal; Azepines; Benzoxazoles; Disease Models, Animal; Drug Evaluation, Preclinical; Feeding and Eating Disorders; Feeding Behavior; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Mice, Transgenic; Motor Activity; Naphthyridines; Narcolepsy; Neuropeptides; Obesity; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Sleep Disorders, Circadian Rhythm; Sleep Disorders, Intrinsic; Substance-Related Disorders; Triazoles; Urea | 2014 |
Suvorexant: first global approval.
Topics: Azepines; Drug Approval; Humans; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2014 |
Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Topics: Azepines; Drug Administration Schedule; Humans; Hypnotics and Sedatives; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2014 |
Suvorexant for the treatment of insomnia.
Topics: Adult; Aged; Animals; Azepines; Dose-Response Relationship, Drug; Drug Approval; Humans; Hypnotics and Sedatives; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles; United States; United States Food and Drug Administration | 2014 |
Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Topics: Azepines; Humans; Hypnotics and Sedatives; Orexin Receptor Antagonists; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles | 2015 |
Suvorexant (Belsomra) for insomnia.
Topics: Animals; Azepines; Clinical Trials as Topic; Humans; Orexin Receptor Antagonists; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2015 |
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Azepines; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2015 |
Profile of suvorexant in the management of insomnia.
Topics: Azepines; Humans; Sleep Initiation and Maintenance Disorders; Triazoles | 2015 |
Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Topics: Azepines; Clinical Trials as Topic; Drug Interactions; Humans; Orexin Receptor Antagonists; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2016 |
New drugs 2016, part 1.
Topics: Aminobutyrates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azabicyclo Compounds; Azepines; Benzazepines; Biphenyl Compounds; Ceftazidime; Drug Approval; Drug Combinations; Humans; Ivabradine; Morphinans; Polyethylene Glycols; Pyridines; Tetrazoles; Thiazoles; Triazoles; United States; United States Food and Drug Administration; Valsartan | 2016 |
Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia.
Topics: Animals; Azepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Orexin Receptor Antagonists; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2016 |
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Topics: Animals; Azepines; Drug Discovery; Humans; Orexin Receptor Antagonists; Orexin Receptors; Protein Structure, Secondary; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Topics: Aged; Aged, 80 and over; Azepines; Benzofurans; Cyclopropanes; Doxepin; Humans; Hypnotics and Sedatives; Indenes; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Topics: Azepines; Humans; Japan; Randomized Controlled Trials as Topic; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; United States | 2017 |
Suvorexant: scientifically interesting, utility uncertain.
Topics: Azepines; Humans; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
Topics: Azepines; Circadian Rhythm; Humans; Life Style; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Quality of Life; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Triazoles | 2018 |
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Topics: Alcoholism; Animals; Azepines; Humans; Orexin Receptor Antagonists; Sleep Wake Disorders; Substance Withdrawal Syndrome; Triazoles | 2020 |
Methyl-containing pharmaceuticals: Methylation in drug design.
Topics: Animals; Azepines; Dogs; Drug Design; Humans; Methylation; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Pharmacology; Piperidines; Pyrimidines; Rats; Solubility; Triazoles | 2018 |
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
Topics: Azepines; Female; Humans; Male; Neuropsychiatry; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2019 |
Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.
Topics: Animals; Azepines; Cocaine-Related Disorders; Humans; Mesencephalon; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Reward; Synaptic Transmission; Triazoles | 2020 |
Toward the Mysteries of Sleep.
Topics: Animals; Azepines; Cataplexy; Humans; Hypothalamus; Mice; Mice, Transgenic; Mutation; Narcolepsy; Nerve Tissue Proteins; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Polysomnography; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Synapses; Triazoles; Wakefulness | 2019 |
Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews.
Topics: Antidepressive Agents; Antipsychotic Agents; Azepines; Benzodiazepines; Cognitive Behavioral Therapy; Comparative Effectiveness Research; Humans; Hypnotics and Sedatives; Melatonin; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Systematic Reviews as Topic; Triazoles; Zolpidem | 2019 |
Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
Topics: Alcoholism; Azepines; Benzodiazepines; Clinical Trials, Phase II as Topic; Comorbidity; Humans; Orexin Receptor Antagonists; Orexin Receptors; Sleep Initiation and Maintenance Disorders; Triazoles | 2020 |
Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Topics: Animals; Azepines; Craving; Drug Repositioning; Humans; Opioid-Related Disorders; Orexin Receptor Antagonists; Triazoles | 2020 |
Prescription Drugs Used in Insomnia.
Topics: Antipsychotic Agents; Azepines; Benzodiazepines; Humans; Melatonin; Orexin Receptor Antagonists; Prescription Drugs; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2020 |
The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
Topics: Aged; Aged, 80 and over; Azepines; Critical Care; Critical Illness; Delirium; Drug Therapy, Combination; Female; Humans; Indenes; Length of Stay; Male; Middle Aged; Orexin Receptor Antagonists; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Retrospective Studies; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2020 |
Effects of orexin receptor antagonism on human sleep architecture: A systematic review.
Topics: Azepines; Healthy Volunteers; Humans; Orexin Receptor Antagonists; Polysomnography; Sleep; Sleep Initiation and Maintenance Disorders; Sleep Stages; Sleep, REM; Triazoles | 2020 |
Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis.
Topics: Azepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2020 |
Suvorexant for the prevention of delirium: A meta-analysis.
Topics: Azepines; Delirium; Humans; Length of Stay; Mortality; Respiration, Artificial; Sleep Aids, Pharmaceutical; Time Factors; Triazoles | 2020 |
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; Orexin Receptor Antagonists; Phenylalanine; Piperidines; Pyridines; Pyrimidines; Sleep Aids, Pharmaceutical; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders; Trazodone; Triazoles; Zolpidem | 2020 |
Pharmacotherapies for sleep disturbances in dementia.
Topics: Alzheimer Disease; Azepines; Caregiver Burden; Cognition; Humans; Indenes; Melatonin; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sleep; Sleep Wake Disorders; Time Factors; Trazodone; Triazoles | 2020 |
Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis.
Topics: Aged; Azepines; Delirium; Humans; Indenes; Randomized Controlled Trials as Topic; Triazoles | 2022 |
Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
Topics: Adult; Azepines; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2022 |
41 trial(s) available for triazoles and suvorexant
Article | Year |
---|---|
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Topics: Adolescent; Adult; Azepines; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Orexin Receptors; Polysomnography; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2012 |
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Topics: Adolescent; Adult; Azepines; Cross-Over Studies; Double-Blind Method; Humans; Hypnotics and Sedatives; Male; Orexin Receptors; Polysomnography; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Sleep; Triazoles; Young Adult | 2013 |
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Topics: Adult; Age Factors; Aged; Azepines; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; Male; Middle Aged; Orexin Receptor Antagonists; Retrospective Studies; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome; Triazoles | 2014 |
Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Topics: Adult; Aged; Azepines; Cross-Over Studies; Double-Blind Method; Electroencephalography; Female; Healthy Volunteers; Humans; Isoxazoles; Male; Middle Aged; Orexin Receptor Antagonists; Polysomnography; Pyridines; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles; Young Adult; Zolpidem | 2014 |
Suvorexant: a novel therapy for the treatment of insomnia.
Topics: Adult; Aged; Aged, 80 and over; Azepines; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2014 |
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Topics: Aged; Azepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Polysomnography; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Wakefulness | 2016 |
Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
Topics: Area Under Curve; Azepines; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Hardness; Healthy Volunteers; Humans; Solubility; Tablets; Triazoles | 2015 |
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azepines; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Pulmonary Disease, Chronic Obstructive; Respiration; Severity of Illness Index; Sleep; Sleep Aids, Pharmaceutical; Spirometry; Treatment Outcome; Triazoles; United States | 2015 |
Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
Topics: Adult; Azepines; Cross-Over Studies; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Oximetry; Oxygen; Polysomnography; Respiration; Sleep Aids, Pharmaceutical; Triazoles | 2015 |
On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
Topics: Adult; Automobile Driving; Azabicyclo Compounds; Azepines; Cross-Over Studies; Double-Blind Method; Female; Healthy Volunteers; Humans; Individuality; Male; Middle Aged; Netherlands; Piperazines; Psychomotor Performance; Self Report; Sleep Aids, Pharmaceutical; Sleep Stages; Triazoles; Young Adult | 2015 |
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
Topics: Adolescent; Adult; Aged; Azepines; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Polysomnography; Respiration; Sleep; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders; Triazoles; Young Adult | 2016 |
Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Topics: Adult; Azepines; Double-Blind Method; Drug Synergism; Ethanol; Female; Healthy Volunteers; Humans; Male; Orexin Receptor Antagonists; Psychomotor Performance; Reaction Time; Triazoles; Young Adult | 2015 |
Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
Topics: Azepines; Electroencephalography; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Polysomnography; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Sleep Stages; Triazoles | 2016 |
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Topics: Adult; Azepines; Cross-Over Studies; Double-Blind Method; Euphoria; Female; Hallucinations; Humans; Hypnotics and Sedatives; Illicit Drugs; Male; Middle Aged; Orexin Receptor Antagonists; Prescription Drug Misuse; Pyridines; Triazoles; Zolpidem | 2016 |
Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Topics: Adolescent; Adult; Aged; Azepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Young Adult | 2016 |
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
Topics: Aged; Aged, 80 and over; Automobile Driving; Azabicyclo Compounds; Azepines; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Hypnotics and Sedatives; Male; Piperazines; Psychomotor Performance; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Time Factors; Triazoles | 2016 |
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Topics: Adult; Aged; Azepines; Disorders of Excessive Somnolence; Double-Blind Method; Female; Humans; Male; Middle Aged; Polysomnography; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Statistics as Topic; Time Factors; Treatment Outcome; Triazoles | 2017 |
Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Topics: Aged; Azepines; Double-Blind Method; Female; Humans; Male; Meta-Analysis as Topic; Polysomnography; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Topics: Aged; Azepines; Data Collection; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Orexin Receptor Antagonists; Placebos; Polysomnography; Problem Solving; Self Report; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles; Wakefulness; Zolpidem | 2018 |
Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Azepines; Female; Humans; Male; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2018 |
Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.
Topics: Adolescent; Adult; Area Under Curve; Azepines; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Headache; Healthy Volunteers; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Sleep Aids, Pharmaceutical; Triazoles; Young Adult | 2018 |
Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
Topics: Aged; Aged, 80 and over; Azepines; Delirium; Drug Therapy, Combination; Female; GABA Agonists; Humans; Indenes; Male; Orexin Receptor Antagonists; Receptors, Melatonin; Retrospective Studies; Risk Factors; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Stroke; Treatment Outcome; Triazoles | 2019 |
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Topics: Adolescent; Adult; Aged; Azepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Outcome Assessment, Health Care; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Triazoles; Young Adult | 2019 |
Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial.
Topics: Azepines; Cross-Over Studies; Equivalence Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; Pilot Projects; Polysomnography; Randomized Controlled Trials as Topic; Sleep; Sleep Aids, Pharmaceutical; Sleep Apnea Syndromes; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2019 |
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Topics: Administration, Oral; Adult; Azepines; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Healthy Volunteers; Humans; Ketoconazole; Male; Middle Aged; Orexin Receptor Antagonists; Rifampin; Triazoles; Young Adult | 2019 |
Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study.
Topics: Antihypertensive Agents; Azepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Female; Humans; Hypertension; Male; Middle Aged; Orexin Receptor Antagonists; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2019 |
Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
Topics: Adult; Aged; Azepines; Female; Humans; Male; Mental Disorders; Middle Aged; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2019 |
Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
Topics: Acoustic Stimulation; Adult; Azepines; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Polysomnography; Sleep Initiation and Maintenance Disorders; Triazoles; Wakefulness; Young Adult | 2019 |
Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors.
Topics: Aged; Azepines; Delirium; Female; Hospitalization; Humans; Indenes; Kaplan-Meier Estimate; Male; Prospective Studies; Risk Factors; Sleep Aids, Pharmaceutical; Treatment Outcome; Triazoles | 2019 |
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
Topics: Aged; Alzheimer Disease; Azepines; Female; Humans; Male; Polysomnography; Sleep; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2020 |
Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
Topics: Adult; Aged; Azepines; Cross-Over Studies; Double-Blind Method; Female; Fibromyalgia; Humans; Middle Aged; Pain; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Young Adult | 2020 |
Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
Topics: Actigraphy; Adult; Azepines; California; Case-Control Studies; Circadian Rhythm; Double-Blind Method; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Placebos; Sleep; Sleep Disorders, Circadian Rhythm; Sleep Initiation and Maintenance Disorders; Triazoles | 2020 |
Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit.
Topics: Adult; Azepines; Delirium; Double-Blind Method; Female; Humans; Intensive Care Units; Middle Aged; Orexin Receptor Antagonists; Pregnancy; Randomized Controlled Trials as Topic; Sleep; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Function, Left | 2020 |
Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
Topics: Acetamides; Adolescent; Adult; Azepines; Benzodiazepines; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Orexin Receptor Antagonists; Pyridines; Pyrimidines; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Young Adult; Zolpidem | 2021 |
Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials.
Topics: Adult; Auditory Perception; Azepines; Benzodiazepines; Cognitive Dysfunction; Discrimination, Psychological; Electroencephalography; Event-Related Potentials, P300; Evoked Potentials, Auditory; Female; Humans; Lorazepam; Male; Orexin Receptor Antagonists; Triazoles; Young Adult | 2021 |
Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Azepines; Humans; Pilot Projects; Polysomnography; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles; Wearable Electronic Devices | 2021 |
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Topics: Azepines; Cross-Over Studies; Double-Blind Method; Drug Users; Humans; Hypnotics and Sedatives; Imidazoles; Orexin Receptor Antagonists; Pyrrolidines; Triazoles; Zolpidem | 2022 |
A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
Topics: Azepines; Double-Blind Method; Female; Humans; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2022 |
Evaluation of suvorexant for trauma-related insomnia.
Topics: Azepines; Double-Blind Method; Humans; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2022 |
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Topics: Analgesics, Opioid; Azepines; Buprenorphine; Craving; Double-Blind Method; Humans; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Sleep; Substance Withdrawal Syndrome; Treatment Outcome; Triazoles | 2022 |
Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
Topics: Aged; Azepines; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Indenes; Male; Orexins; Triazoles; Zolpidem | 2022 |
101 other study(ies) available for triazoles and suvorexant
Article | Year |
---|---|
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Topics: Animals; Azepines; Biological Availability; CHO Cells; Cricetinae; Cricetulus; Dogs; Humans; In Vitro Techniques; Male; Microsomes, Liver; Orexin Receptors; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Sleep; Sleep Initiation and Maintenance Disorders; Stereoisomerism; Structure-Activity Relationship; Telemetry; Triazoles; Wakefulness | 2010 |
Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Topics: Animals; Area Under Curve; Azepines; Azides; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Electrocardiography; Electromyography; Humans; Macaca mulatta; Motor Activity; Octreotide; Orexin Receptors; Protein Binding; Rats; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Sleep; Transfection; Triazoles | 2011 |
Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305).
Topics: Amination; Azepines; Catalysis; Hydrogenation; Intracellular Signaling Peptides and Proteins; Kinetics; Neuropeptides; Orexins; Ruthenium; Stereoisomerism; Triazoles | 2011 |
Enantioselective synthesis of a dual orexin receptor antagonist.
Topics: Azepines; Molecular Structure; Orexin Receptors; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2012 |
New class of sleep drugs may offer a safer night's rest.
Topics: Azepines; Clinical Trials as Topic; Humans; Intracellular Signaling Peptides and Proteins; Neuropeptides; Orexins; Patient Safety; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles; United States; United States Food and Drug Administration | 2012 |
Insomnia: chasing the dream.
Topics: Animals; Arousal; Azabicyclo Compounds; Azepines; Benzodiazepines; Cognitive Behavioral Therapy; Doxepin; Dreams; Histamine Agonists; Histamine Antagonists; Humans; Hypnotics and Sedatives; Hypothalamus; Orexin Receptors; Piperazines; Piperidines; Receptors, G-Protein-Coupled; Receptors, GABA; Receptors, Histamine H3; Receptors, Neuropeptide; Sleep Initiation and Maintenance Disorders; Triazoles | 2013 |
The top 10 drug trends right now.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Azepines; Biphenyl Compounds; Canagliflozin; Cholesterol Ester Transfer Proteins; Dimethyl Fumarate; Drug Approval; Forecasting; Fumarates; gamma-Cyclodextrins; Glucosides; Humans; Lactones; Maytansine; Pyridines; Sofosbuvir; Sugammadex; Thiophenes; Trastuzumab; Triazoles; United States; United States Food and Drug Administration; Uridine Monophosphate | 2013 |
First-in-class insomnia drug on the brink of approval nod.
Topics: Azepines; Clinical Trials as Topic; Drug Approval; Humans; Orexin Receptors; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Sleep Initiation and Maintenance Disorders; Triazoles; United States; United States Food and Drug Administration | 2013 |
Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Topics: Animals; Azepines; Electroencephalography; Electromyography; Indoles; Male; Mice; Mice, Inbred C57BL; Motor Activity; Orexin Receptor Antagonists; Pyrimidines; Quinoxalines; Sleep; Sleep Initiation and Maintenance Disorders; Sleep Stages; Spiro Compounds; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2013 |
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.
Topics: Animals; Azepines; Dogs; Electroencephalography; Female; Humans; Immunoassay; Intracellular Signaling Peptides and Proteins; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Neuropeptides; Orexin Receptor Antagonists; Orexins; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sleep; Triazoles | 2013 |
Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs.
Topics: Azepines; Crystallography, X-Ray; Humans; Ligands; Magnetic Resonance Spectroscopy; Molecular Conformation; Molecular Structure; Orexin Receptor Antagonists; Orexin Receptors; Triazoles | 2014 |
Orexin receptor antagonists: a new treatment for insomnia?
Topics: Azepines; Female; Humans; Hypnotics and Sedatives; Male; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2014 |
Suvorexant approved for insomnia.
Topics: Azepines; Humans; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2014 |
Insomniacs get new mechanism sleep drug Belsomra.
Topics: Azepines; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans; Sleep Initiation and Maintenance Disorders; Triazoles | 2014 |
Suvorexant: something new for sleep?
Topics: Animals; Azepines; Drug Interactions; Humans; Hypnotics and Sedatives; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2015 |
CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Topics: Aprepitant; Azepines; Benzazepines; Central Nervous System Agents; Drug Discovery; History, 20th Century; History, 21st Century; Humans; Indenes; Morpholines; Neurotransmitter Agents; Ondansetron; Quinoxalines; Triazoles; Varenicline | 2014 |
Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
Topics: Azepines; Crystallography, X-Ray; Humans; Molecular Docking Simulation; Orexin Receptor Antagonists; Orexin Receptors; Protein Conformation; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Sleep Initiation and Maintenance Disorders; Triazoles | 2015 |
Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection.
Topics: Azepines; Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Sleep Aids, Pharmaceutical; Tandem Mass Spectrometry; Triazoles | 2015 |
In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
Topics: Adult; Azepines; Female; Healthy Volunteers; Humans; Male; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2016 |
Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
Topics: Azepines; Crystallography, X-Ray; Humans; Ligands; Models, Molecular; Orexin Receptor Antagonists; Orexin Receptors; Protein Binding; Protein Conformation; Pyrrolidines; Thiazoles; Triazoles | 2016 |
Galaxy7TM: flexible GPCR-ligand docking by structure refinement.
Topics: Azepines; Humans; Internet; Ligands; Molecular Docking Simulation; Orexin Receptors; Receptors, G-Protein-Coupled; Software; Triazoles | 2016 |
Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem.
Topics: Aged, 80 and over; Azepines; Diltiazem; Drug Interactions; Female; Humans; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Triazoles | 2016 |
Suvorexant (Belsomra) for Insomnia.
Topics: Azepines; Education, Medical, Continuing; Humans; Practice Guidelines as Topic; Practice Patterns, Physicians'; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2016 |
Mechanism of action of suvorexant.
Topics: Arousal; Azepines; Humans; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles; Wakefulness | 2016 |
Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
Topics: Adult; Aged; Azepines; Cross-Over Studies; Double-Blind Method; Electroencephalography; Healthy Volunteers; Humans; Hypnotics and Sedatives; Male; Middle Aged; Orexin Receptor Antagonists; Polysomnography; Pyridines; Sleep; Triazoles; Zolpidem | 2016 |
Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
Topics: Adipose Tissue; Animals; Azepines; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucose; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Orexin Receptor Antagonists; Orexins; Receptors, Leptin; Sleep; Triazoles; Triglycerides; Wakefulness | 2016 |
Quantification of suvorexant in urine using gas chromatography/mass spectrometry.
Topics: Azepines; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Limit of Detection; Liquid-Liquid Extraction; Sleep Aids, Pharmaceutical; Triazoles | 2017 |
Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS).
Topics: Azepines; Calibration; Chromatography, Liquid; Forensic Toxicology; Humans; Limit of Detection; Liquid-Liquid Extraction; Mass Spectrometry; Molecular Structure; Orexin Receptor Antagonists; Reproducibility of Results; Sleep Aids, Pharmaceutical; Triazoles | 2017 |
Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report.
Topics: Aged; Azepines; Dreams; Humans; Male; Parasomnias; Parkinson Disease; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
Topics: Animals; Azepines; Humans; Hypnotics and Sedatives; Macaca mulatta; Orexin Receptor Antagonists; Rats; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Substance-Related Disorders; Triazoles | 2017 |
Simple and Highly Sensitive UPLC-ESI-MS/MS Assay for Rapid Determination of Suvorexant in Plasma.
Topics: Animals; Azepines; Chromatography, Liquid; Illicit Drugs; Limit of Detection; Male; Rats; Rats, Wistar; Reproducibility of Results; Sleep Aids, Pharmaceutical; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2017 |
Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
Topics: Animals; Azepines; Behavior, Animal; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Locomotion; Male; Motivation; Orexin Receptor Antagonists; Rats; Reinforcement, Psychology; Reward; Self Administration; Triazoles; Ventral Striatum | 2018 |
A Case of Persistent Delirium Resolved Promptly With Suvorexant.
Topics: Azepines; Delirium; Humans; Male; Middle Aged; Psychotropic Drugs; Triazoles | 2017 |
Suvorexant for the Treatment of Insomnia in Adolescents.
Topics: Adolescent; Azepines; Dreams; Female; Humans; Male; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2017 |
Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
Topics: Animals; Azepines; Benzoxazoles; Choice Behavior; Cocaine; Delay Discounting; Impulsive Behavior; Isoquinolines; Male; Microinjections; Naphthyridines; Orexin Receptor Antagonists; Orexins; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Triazoles; Urea; Ventral Tegmental Area | 2018 |
Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Azepines; Female; Humans; Schizophrenia; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2017 |
Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats.
Topics: Animals; Azepines; Benzodioxoles; Craving; Dopaminergic Neurons; Dose-Response Relationship, Drug; Infusions, Intravenous; Male; Mesencephalon; Orexin Receptors; Pyrrolidines; Rats; Rats, Sprague-Dawley; Self Administration; Synthetic Cathinone; Triazoles; Vocalization, Animal | 2017 |
Benefits of switching to suvorexant for mild primary insomnia when sleepwalking episodes occur during zolpidem treatment.
Topics: Adult; Azepines; Female; GABA-A Receptor Agonists; Humans; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Somnambulism; Treatment Outcome; Triazoles; Zolpidem | 2017 |
Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.
Topics: Adult; Azepines; Blood Glucose; Comorbidity; Humans; Mental Disorders; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints.
Topics: Azepines; Clinical Trial Protocols as Topic; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Discovery; Endpoint Determination; Humans; Models, Statistical; Research Design; Triazoles | 2018 |
Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.
Topics: Adult; Azepines; Benzodiazepines; Female; Humans; Hypnotics and Sedatives; Muscle Hypotonia; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Treatment Outcome; Triazoles | 2017 |
Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
Topics: Antidepressive Agents; Azepines; Depressive Disorder, Major; Diagnosis, Differential; Female; Humans; Hypnotics and Sedatives; Middle Aged; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Suicidal Ideation; Treatment Outcome; Triazoles | 2017 |
Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases.
Topics: Adult; Aged, 80 and over; Autopsy; Azepines; Chromatography, Liquid; Female; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Tandem Mass Spectrometry; Tissue Distribution; Triazoles | 2018 |
Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.
Topics: Aged; Azepines; Bed Occupancy; Critical Care; Delirium; Female; Humans; Incidence; Intensive Care Units; Japan; Length of Stay; Male; Orexin Receptor Antagonists; Retrospective Studies; Sleep Aids, Pharmaceutical; Treatment Outcome; Triazoles | 2018 |
CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug-Suvorexant as an Example.
Topics: Animals; Azepines; Central Nervous System Agents; Drug Approval; Drug Development; Female; Humans; Male; Pregnancy; Triazoles | 2018 |
[Usefulness of Suvorexant for Complicated Delirium in Cancer Patients Who Experience Sleep Disturbance during Hospitalization].
Topics: Azepines; Delirium; Follow-Up Studies; Hospitalization; Humans; Neoplasms; Retrospective Studies; Sleep Aids, Pharmaceutical; Triazoles | 2018 |
Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort.
Topics: Aged; Aged, 80 and over; Azepines; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Female; Hip Fractures; Humans; Hypnotics and Sedatives; Japan; Male; Models, Econometric; Pyridines; Quality-Adjusted Life Years; Sleep Initiation and Maintenance Disorders; Triazoles; Zolpidem | 2018 |
Effects of an orexin receptor antagonist on blood pressure and metabolic parameters.
Topics: Adult; Aged; Animals; Azepines; Blood Pressure; Cholesterol, HDL; Female; Glucose; Humans; Hypertension; Male; Mice; Middle Aged; Models, Animal; Orexin Receptor Antagonists; Prospective Studies; Republic of Korea; Retrospective Studies; Sleep Wake Disorders; Triazoles | 2018 |
Quantification of suvorexant in blood using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry.
Topics: Animals; Azepines; Cattle; Chromatography, Liquid; Limit of Detection; Linear Models; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Triazoles | 2018 |
Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting.
Topics: Aged; Azepines; Checklist; Coronary Artery Bypass; Delirium; Drug Administration Schedule; Female; Humans; Length of Stay; Male; Middle Aged; Orexin Receptor Antagonists; Retrospective Studies; Time Factors; Treatment Outcome; Triazoles | 2019 |
Simultaneous Detection and Quantification of Three Novel Prescription Drugs of Abuse (Suvorexant, Lorcaserin and Brivaracetam) in Human Plasma by UPLC-MS-MS.
Topics: Azepines; Benzazepines; Calibration; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Liquid-Liquid Extraction; Prescription Drugs; Pyrrolidinones; Reference Standards; Reproducibility of Results; Substance Abuse Detection; Substance-Related Disorders; Tandem Mass Spectrometry; Triazoles | 2019 |
Suvorexant-Induced Delirium.
Topics: Aged, 80 and over; Azepines; Delirium; Humans; Male; Orexin Receptor Antagonists; Sleep Initiation and Maintenance Disorders; Triazoles | 2018 |
Suvorexant (Belsomra
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azepines; Drug Utilization Review; Female; Humans; Japan; Male; Middle Aged; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Sleep Latency; Surveys and Questionnaires; Tablets; Triazoles; Young Adult | 2019 |
Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
Topics: Alcoholism; Animals; Azepines; Electroencephalography; Ethanol; Humans; Male; Orexin Receptor Antagonists; Rats; Rats, Wistar; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Sleep, REM; Sleep, Slow-Wave; Substance Withdrawal Syndrome; Time Factors; Triazoles | 2019 |
Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study.
Topics: Amino Acid Sequence; Azepines; Binding Sites; Humans; Molecular Dynamics Simulation; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Protein Binding; Protein Conformation; Triazoles; Water | 2019 |
Insomnia and hypertension: A misty landscape.
Topics: Azepines; Blood Pressure; Humans; Hypertension; Sleep Initiation and Maintenance Disorders; Triazoles | 2019 |
Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
Topics: Azepines; Humans; Polysomnography; Sleep Aids, Pharmaceutical; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders; Triazoles | 2019 |
Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.
Topics: Animals; Azepines; Cognitive Dysfunction; Disease Models, Animal; Female; Huntington Disease; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Orexin Receptor Antagonists; Orexins; Sleep Disorders, Circadian Rhythm; Triazoles | 2019 |
Use of Suvorexant for Sleep Regulation in an Adolescent with Early-Onset Bipolar Disorder.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Azepines; Bipolar Disorder; Humans; Lurasidone Hydrochloride; Male; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles; Valproic Acid | 2019 |
Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Topics: Animals; Azepines; Cytochrome P-450 CYP3A; Dogs; Half-Life; Humans; Inhibitory Concentration 50; Orexin Receptor Antagonists; Orexin Receptors; Oxadiazoles; Rats; Sleep; Structure-Activity Relationship; Triazoles | 2019 |
Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
Topics: Aged; Azepines; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Product Surveillance, Postmarketing; Prospective Studies; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2019 |
Palladium-Catalyzed Decarboxylative Asymmetric Allylic Alkylation of 1,4-Diazepan-5-ones.
Topics: Alkylation; Azepines; Catalysis; Palladium; Sleep Aids, Pharmaceutical; Triazoles | 2019 |
Identification of Suvorexant in Blood Using LC-MS-MS: Important Considerations for Matrix Effects and Quantitative Interferences in Targeted Assays.
Topics: Azepines; Biological Assay; Chromatography, Liquid; Forensic Toxicology; Humans; Limit of Detection; Sleep Aids, Pharmaceutical; Tandem Mass Spectrometry; Triazoles | 2020 |
Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan.
Topics: Aged; Azepines; Dizziness; Female; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Triazoles | 2020 |
A simple method using anesthetics to test effects of sleep-inducing substances in mice.
Topics: Anesthesia; Anesthetics; Animals; Azepines; Butorphanol; Chlorpromazine; Drug Combinations; Imidazoles; Indenes; Isoflurane; Male; Medetomidine; Mice; Mice, Inbred ICR; Midazolam; Orexin Receptor Antagonists; Sleep Aids, Pharmaceutical; Triazoles | 2020 |
How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?
Topics: Age Factors; Analgesics; Azepines; Female; Humans; Isoxazoles; Male; Middle Aged; Polysomnography; Predictive Value of Tests; Sleep Aids, Pharmaceutical; Sleep Hygiene; Sleep Initiation and Maintenance Disorders; Time Factors; Triazoles | 2020 |
Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
Topics: Azepines; Calorimetry, Differential Scanning; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Contamination; Magnetic Resonance Spectroscopy; Molecular Structure; Oxidation-Reduction; Spectroscopy, Fourier Transform Infrared; Tandem Mass Spectrometry; Triazoles | 2020 |
Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Azepines; Chronobiology Disorders; Cognitive Dysfunction; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Gene Expression; Hippocampus; Long-Term Potentiation; Mice, Transgenic; Neuronal Plasticity; Neuroprostanes; Orexin Receptor Antagonists; Orexins; Triazoles | 2020 |
A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis.
Topics: Animals; Azepines; Behavior, Animal; Biological Products; HEK293 Cells; Humans; Molecular Docking Simulation; Orexin Receptor Antagonists; Orexin Receptors; Plants; Triazoles; Zebrafish | 2020 |
CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens.
Topics: Azepines; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Forensic Toxicology; Humans; Isoenzymes; Mass Spectrometry; Sleep Aids, Pharmaceutical; Triazoles | 2020 |
Association of Hypnotic Drug Use with Fall Incidents in Hospitalized Elderly Patients: A Case-Crossover Study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Azepines; Cross-Over Studies; Female; GABA-A Receptor Agonists; Hospitalization; Humans; Hypnotics and Sedatives; Indenes; Japan; Male; Receptors, GABA-A; Risk Factors; Triazoles | 2020 |
Drug-mediated ion suppression and mitigation of interferences using liquid chromatography-quadrupole/time of flight mass spectrometry (LC-Q/TOF-MS) and liquid chromatography tandem mass spectrometry (LC-MS/MS).
Topics: Azepines; Chromatography, Liquid; Forensic Toxicology; Ions; Models, Chemical; Pharmaceutical Preparations; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2020 |
[Association Suvorexant and Ramelteon Use with the Risk of Falling: A Retrospective Case-control Study].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Azepines; Body Mass Index; Case-Control Studies; Female; Humans; Hypnotics and Sedatives; Indenes; Male; Middle Aged; Retrospective Studies; Triazoles | 2020 |
Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
Topics: Aged; Azepines; Diabetes Mellitus, Type 2; Drug Chronotherapy; Female; Humans; Male; Prospective Studies; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Triazoles | 2020 |
Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Azepines; Benzodiazepines; Cross-Over Studies; Female; Humans; Hypnotics and Sedatives; Indenes; Male; Middle Aged; Risk Factors; Sleep; Sleep Aids, Pharmaceutical; Triazoles | 2020 |
Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder.
Topics: Autism Spectrum Disorder; Azepines; Drug Therapy, Combination; Female; Humans; Indenes; Sleep Aids, Pharmaceutical; Sleep Disorders, Circadian Rhythm; Treatment Outcome; Triazoles; Young Adult | 2020 |
Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azepines; Child; Child, Preschool; Critical Care; Delirium; Female; Humans; Male; Middle Aged; Orexin Receptor Antagonists; Outcome Assessment, Health Care; Prevalence; Proportional Hazards Models; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Trazodone; Triazoles; Young Adult | 2020 |
Syndrome of inappropriate antidiuretic hormone secretion induced by suvorexant: a case report.
Topics: Aged; Azepines; Diabetes Mellitus, Type 2; Humans; Inappropriate ADH Syndrome; Male; Triazoles | 2021 |
Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
Topics: Amygdala; Animals; Azepines; Corticosterone; Disease Models, Animal; Male; Orexin Receptor Antagonists; Orexins; Paroxetine; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic; Triazoles | 2021 |
Quetiapine may complete the best match with suvorexant in psychiatric patients with insomnia.
Topics: Azepines; Humans; Quetiapine Fumarate; Sleep Initiation and Maintenance Disorders; Triazoles | 2021 |
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation.
Topics: Aminopyridines; Azepines; Binding Sites; Cloning, Molecular; Cryoelectron Microscopy; Escherichia coli; Gene Expression; Genetic Vectors; HEK293 Cells; Humans; Molecular Dynamics Simulation; Orexin Receptor Antagonists; Orexin Receptors; Peptides; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Recombinant Proteins; Sleep Aids, Pharmaceutical; Sulfonamides; Triazoles | 2021 |
Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder: a case series of three patients.
Topics: Adult; Azepines; Disorders of Excessive Somnolence; Female; Humans; Indenes; Male; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles; Young Adult | 2021 |
Effect of suvorexant on morphine tolerance and dependence in mice: Role of NMDA, AMPA, ERK and CREB proteins.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analgesics, Opioid; Animals; Azepines; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Drug Tolerance; Male; MAP Kinase Signaling System; Mice; Morphine; Morphine Dependence; N-Methylaspartate; Triazoles | 2021 |
Significant decrease in delirium referrals after changing hypnotic from benzodiazepine to suvorexant.
Topics: Aged; Azepines; Benzodiazepines; Delirium; Humans; Hypnotics and Sedatives; Referral and Consultation; Sleep Initiation and Maintenance Disorders; Triazoles | 2021 |
Influence of light-dark cycle on delayed recovery from isoflurane anesthesia induced by hypnotics in mice.
Topics: Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Azepines; Chronopharmacokinetics; Circadian Rhythm; GABAergic Neurons; Hypnotics and Sedatives; Isoflurane; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred ICR; Motor Activity; Photoperiod; Time Factors; Triazoles | 2021 |
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture.
Topics: Azepines; Child; Cross-Over Studies; Double-Blind Method; Humans; Male; Nocturnal Enuresis; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles | 2021 |
Novel and Nonroutine Benzodiazepines and Suvorexant by LC-MS-MS.
Topics: Azepines; Benzodiazepines; Chromatography, Liquid; Designer Drugs; Limit of Detection; Tandem Mass Spectrometry; Triazoles | 2021 |
Studies Support the Use of Suvorexant for the Prevention of Delirium.
Topics: Azepines; Delirium; Humans; Triazoles | 2021 |
It Is Too Early to Put Delirium Prophylaxis to Bed: Stronger Evidence Is Needed for Suvorexant.
Topics: Azepines; Delirium; Humans; Triazoles | 2021 |
[Standardization of Hypnotic Agents for Prevention of Falls: A Pharmacoeconomic Study].
Topics: Accidental Falls; Aged; Aged, 80 and over; Azepines; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Eszopiclone; Female; Hospitalization; Humans; Hypnotics and Sedatives; Male; Middle Aged; Sleep Initiation and Maintenance Disorders; Triazoles | 2021 |
Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant.
Topics: Aged; Azepines; Delivery of Health Care; Female; Health Care Costs; Humans; Male; Medicare; Middle Aged; Retrospective Studies; Sleep Initiation and Maintenance Disorders; Triazoles; United States | 2021 |
Differential sleep/wake response and sex differences following acute suvorexant, MK-1064 and zolpidem administration in the rTg4510 mouse model of tauopathy.
Topics: Animals; Azepines; Disease Models, Animal; Female; Hypnotics and Sedatives; Male; Mice; Mice, Transgenic; Sex Characteristics; Sleep; Sleep Wake Disorders; Tauopathies; Triazoles; Zolpidem | 2022 |
Suvorexant and mirtazapine improve chronic pain-related changes in parameters of sleep and voluntary physical performance in mice with sciatic nerve ligation.
Topics: Animals; Azepines; Chronic Pain; Male; Mice; Mirtazapine; Sciatic Nerve; Sleep, REM; Triazoles | 2022 |
Suvorexant for Primary Insomnia in a Patient at High Risk for Hypnotic Dependence.
Topics: Azepines; Humans; Hypnotics and Sedatives; Sleep Initiation and Maintenance Disorders; Triazoles | 2022 |
Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders.
Topics: Azepines; Humans; Pyridines; Pyrimidines; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles | 2022 |
Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia.
Topics: Animals; Azepines; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Pain; Pharmaceutical Preparations; Triazoles | 2022 |
Dual orexin receptor blocker suvorexant attenuates hypercapnic ventilatory augmentation in mice.
Topics: Animals; Azepines; Carbon Dioxide; Hypercapnia; Mice; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Receptors, Neurokinin-1; Somatostatin; Transcription Factors; Triazoles | 2022 |
Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.
Topics: Animals; Azepines; Cocaine; Humans; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Triazoles | 2022 |
Interaction between the Human OX2 Orexin Receptor and Suvorexant and Some of Its Analogues: SAPT (DFT) Interaction Energy Decomposition Analysis.
Topics: Azepines; Benzoxazoles; Humans; Ligands; Molecular Docking Simulation; Orexin Receptor Antagonists; Orexin Receptors; Quantum Theory; Triazoles | 2022 |
Suvorexant for Preventing Alzheimer's Disease.
Topics: Alzheimer Disease; Azepines; Humans; Sleep Initiation and Maintenance Disorders; Triazoles | 2023 |
Reply to Suvorexant for Preventing Alzheimer's Disease.
Topics: Alzheimer Disease; Azepines; Humans; Triazoles | 2023 |